EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

BRAF(V600E) is the most common oncogenic lesion in melanoma and results in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncogenic signaling, restrain cellular g...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Discov
Autors principals: Miao, Benchun, Ji, Zhenyu, Tan, Li, Taylor, Michael, Zhang, Jianming, Choi, Hwan Geun, Frederick, Dennie T., Kumar, Raj, Wargo, Jennifer A., Flaherty, Keith T., Gray, Nathanael S., Tsao, Hensin
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355085/
https://ncbi.nlm.nih.gov/pubmed/25542448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0295
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars